ClinicalTrials.gg
CompletedNCT01709214Updated Jul 15, 2021

Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

A Phase 2 interventional study of Cebranopadol (GRT6005) Low-Dose Range and Cebranopadol (GRT6005) High-Dose Range in Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee, sponsored by Tris Pharma, Inc.. Completed at 83 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2014, 12 years 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Feb 2019.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
619
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.

Enrollment
64th of 832
619 · median 100
Started
2012
with 50 others
Phase 2
121 of 1,029
9 open now
Registered
414th of 1,029
by date

Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 64th largest by enrollment of the 832 interventional ones that give a count, is one of 51 that started in 2012, is one of 121 in phase 2, and was the 414th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,029 studies in Osteoarthritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are eligible for the Double-blind Treatment Period will be randomized to one of following treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or placebo.

03

Conditions studied

  • Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Keywords

  • Osteoarthritis
  • Knee
  • Pain
  • Chronic
  • OA
  • Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of osteoarthritis (OA) of the knee
  • OA knee pain present for at least 3 months
  • OA knee pain is the predominant (ie, most painful) pain condition
  • Patients require medication on at least 4 of 7 days per week to treat OA knee pain for at least 1 month.
  • Dissatisfaction with current OA knee pain treatment and willingness to stop taking all pain medications except for the study drug and allowed rescue medication
  • Average daily pain rating of at least 5 on a 0 to 10 point numerical rating scale during the 1 week prior to randomization
  • Female patients either , surgically sterile or practicing a medically acceptable method of
  • Male patients either status post-bilateral vasectomy or using barrier contraception

Exclusion criteria

Exclusion Criteria:

  • Knee pain due to a disorder other than OA
  • Other pain that can confound the assessment of, or contribute to, pain at the reference knee
  • Surgery at the reference knee within 6 months of Screening or a history of joint replacement surgery at the reference knee
  • Trauma to the reference knee within 6 months of Screening with active symptoms
  • injections in the reference knee within 3 months of Screening
  • Hyaluronic acid injections in the reference knee within 6 months of Screening
  • > 40 kg/m2
  • Patient with any protocol-excluded or medical, surgical, or medication history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
619 participants (actual)

Study arms

  • Experimental
    Cebranopadol (GRT6005) Low-Dose Range

    Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks

    Drug: Cebranopadol (GRT6005) Low-Dose Range · Drug: Placebo

  • Experimental
    Cebranopadol (GRT6005) High-Dose Range

    Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks

    Drug: Cebranopadol (GRT6005) High-Dose Range · Drug: Placebo

  • Placebo comparator
    Placebo

    Twice daily Placebo, oral administration for 15 weeks

    Drug: Placebo

  • Active comparator
    Oxycodone CR

    Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks

    Drug: Oxycodone CR

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the weekly average of the daily average pain rating

    Time frame: Baseline to end of treatment (Week 15)

Secondary outcomes

  1. Change from baseline in the physical function subscale of the Western Ontario and McMaster University Index of Osteoarthritis Questionnaire (WOMAC)

    Time frame: Baseline to end of treatment (Week 15)

07

Study locations

83 sites
  • Site 051
    Birmingham, Alabama 35209, United States
  • Site 022
    Birmingham, Alabama 35216, United States
  • Site 031
    Huntsville, Alabama 35801, United States
  • Site 005
    Phoenix, Arizona 85018, United States
  • Site 018
    Phoenix, Arizona 85023, United States
  • Site 070
    Phoenix, Arizona 85027, United States
  • Site 028
    Tucson, Arizona 85712, United States
  • Site 081
    Chino, California 91710, United States
  • Site 030
    El Cajon, California 92020, United States
  • Site 039
    Fair Oaks, California 95628, United States
  • Site 061
    Fresno, California 93726, United States
  • Site 084
    North Hollywood, California 91606, United States
  • Site 080
    Roseville, California 95661, United States
  • Site 004
    Sacramento, California 95821, United States
  • Site 044
    San Diego, California 92117, United States
  • Site 043
    Tustin, California 92780, United States
  • Site 010
    Walnut Creek, California 94598, United States
  • Site 027
    Westlake Village, California 91361, United States
  • Site 011
    Bradenton, Florida 34209, United States
  • Site 071
    Clearwater, Florida 33761, United States
  • Site 090
    Edgewater, Florida 32132, United States
  • Site 060
    Jacksonville, Florida 32256, United States
  • Site 015
    Jupiter, Florida 33458, United States
  • Site 013
    Miami, Florida 33144, United States
  • Site 003
    New Port Richey, Florida 34652, United States
  • Site 012
    Ocala, Florida 34474, United States
  • Site 032
    Orlando, Florida 32806, United States
  • Site 025
    Ormond Beach, Florida 32174, United States
  • Site 058
    Pembroke Pines, Florida 33028, United States
  • Site 091
    Pinellas Park, Florida 33781, United States
  • Site 007
    Sarasota, Florida 34238, United States
  • Site 052
    Marietta, Georgia 30066, United States
  • Site 033
    Perry, Georgia 31069, United States
  • Site 073
    Stockbridge, Georgia 30281, United States
  • Site 086
    Chicago, Illinois 60612, United States
  • Site 041
    Indianapolis, Indiana 46260, United States
  • Site 085
    Valparaiso, Indiana 46383, United States
  • Site 088
    Towson, Maryland 21204, United States
  • Site 077
    Wheaton, Maryland 20902, United States
  • Site 083
    New Bedford, Massachusetts 02740, United States
  • Site 021
    North Dartmouth, Massachusetts 02747, United States
  • Site 020
    Worcester, Massachusetts 01605, United States
  • Site 016
    Bingham Farms, Michigan 48025, United States
  • Site 042
    Traverse City, Michigan 49684, United States
  • Site 023
    Saint Louis, Missouri 63141, United States
  • Site 087
    Grand Island, Nebraska 68803, United States
  • Site 074
    Omaha, Nebraska 68144, United States
  • Site 024
    Las Vegas, Nevada 89130, United States
  • Site 072
    Las Vegas, Nevada 89144, United States
  • Site 009
    Albuquerque, New Mexico 87102, United States
  • Site 068
    Albany, New York 12208, United States
  • Site 017
    Hartsdale, New York 10530, United States
  • Site 056
    Greensboro, North Carolina 27410, United States
  • Site 006
    High Point, North Carolina 27262, United States
  • Site 078
    Wilmington, North Carolina 28401, United States
  • Site 079
    Cincinnati, Ohio 45219, United States
  • Site 008
    Cincinnati, Ohio 45242, United States
  • Site 069
    Cleveland, Ohio 44122, United States
  • Site 001
    Columbus, Ohio 43213, United States
  • Site 048
    Toledo, Ohio 43623, United States
  • Site 075
    Oklahoma City, Oklahoma 73103, United States
  • Site 029
    Bend, Oregon 97701, United States
  • Site 067
    Medford, Oregon 97504, United States
  • Site 035
    Portland, Oregon 97239, United States
  • Site 045
    Altoona, Pennsylvania 16602, United States
  • Site 002
    Duncansville, Pennsylvania 16635, United States
  • Site 034
    Anderson, South Carolina 29621, United States
  • Site 076
    Charleston, South Carolina 29407, United States
  • Site 093
    Bristol, Tennessee 37620, United States
  • Site 055
    Austin, Texas 78731, United States
  • Site 049
    Bryan, Texas 77802, United States
  • Site 038
    Dallas, Texas 75203, United States
  • Site 089
    San Antonio, Texas 78209, United States
  • Site 040
    San Antonio, Texas 78229, United States
  • Site 082
    Wichita Falls, Texas 76309, United States
  • Site 019
    Draper, Utah 84020, United States
  • Site 064
    Ogden, Utah 84405, United States
  • Site 059
    Salt Lake City, Utah 84106, United States
  • Site 092
    Norfolk, Virginia 23507, United States
  • Site 026
    Virginia Beach, Virginia 23454, United States
  • Site 066
    Bellevue, Washington 98007, United States
  • Site 057
    Renton, Washington 98057, United States
  • Site 065
    Seattle, Washington 98122, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Apr 2014, 16 months.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 16 months is close to that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
StartActual
Dec 4, 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 4, 2014
Results delay requested
Feb 18, 2019
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01709214
Lead sponsor
Tris Pharma, Inc.
Collaborators
Forest Laboratories
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Dec 4, 2012
Primary completion
Apr 2014
Completion
Apr 4, 2014
Last update
Jul 15, 2021

Study contacts

Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion